

# **Circulating Tumor Cells and Cancer Stem Cells Technologies: Market Research Report**

<https://marketpublishers.com/r/C62E23E7420EN.html>

Date: January 2014

Pages: 213

Price: US\$ 4,950.00 (Single User License)

ID: C62E23E7420EN

## **Abstracts**

This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US\$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 66 companies including many key and niche players such as -

Alchemia Limited

Amgen Inc.

Exelixis, Inc.

Formula Pharmaceuticals

GlaxoSmithKline Plc

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. CIRCULATING TUMOR CELLS (CTCS) - GLOBAL MARKET OVERVIEW

CTC Detection – Real-Time ‘Liquid Biopsy’ Scores Over Surgical Biopsy

Challenges in CTC Diagnostics

Need for CTC Enrichment and Popular Methods

CTC Enrichment Techniques

CTC Identification – Various Approaches

#### CTC IDENTIFICATION APPROACHES

A List of mRNA Markers for RT-PCR–based Detection of CTCs by Tumor Type  
CellSearch System- The Only FDA Approved Automated Enrichment/Isolation  
Technique

Market Outlook

Rising Incidence of Cancer – An Opportunity Indicator

**Table 1.** World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)

**Table 2.** World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)

**Table 3.** New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart)

**Table 4.** Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding Graph/Chart)

**Table 5.** Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart)

**Table 6.** Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart)

**Table 7.** Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart)

Cancer Prone Sites based on Age

## **2. MARKET TRENDS AND DRIVERS**

CTCs for Personalized Cancer Treatment

Microfluidic Chip-based Technologies – A Promising Avenue for Cancer Diagnosis

CTC Microdevices Hog the Limelight

**Table 8.** Select CTC Microdevices and Their Characteristics

Limitations of CTC Technology for Point-of-Care Testing

CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis

Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?

## **3. CANCER STEM CELLS - GLOBAL MARKET OVERVIEW**

CSC-Focused Innovations in Cancer Therapeutics

Select Pathways or Molecular Targets for CSC Candidates

Pipeline Analysis of Select Cancer Stem Cells Therapeutics (2014)

Select Targeted Toxins against CSC Markers: 2013

Various Methods Used for Isolation of Cancer Stem Cells

Antibody-mediated Therapies

#### 4. CTC AND CSC RESEARCH FINDINGS & BREAKTHROUGHS

Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity

NBiomics Makes its Contribution to CTC Diagnosis

Researchers at University of Michigan Develop Revolutionary Capture CTCs Method Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis

Gold Nanoparticles Help in the Detection of CTCs

Diabetes Drug Metformin May Prove Effective against Pancreatic Cancer Stem Cells

Novel Chemical Inhibitors that Target Cancer Stem Cells

#### 5. MEDICAL DIAGNOSTICS MARKET – A CONCEPTUAL OVERVIEW

Clinical Diagnostics

**Table 9.** Leading Players in the Global In Vitro Diagnostics (IVD) Market (2013) – Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)

**Table 10.** Global In-Vitro Diagnostics (IVD) Market (2013): Percentage Breakdown for Value Sales by Segment for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)

Molecular Diagnostics – Growth Drivers

Molecular Diagnostics for Lymphoid Malignancies

Market Trends & Issues

Global Molecular Diagnostics on a High Growth Curve

Automation Driving Global Market

Molecular Diagnostics: Marking Convergence of Numerous Technologies

Aging Population, Disease Incidence – Fundamental Drivers of Growth

Pharmaceutical Firms Carving their Niche in the Molecular Diagnostics Market

Limited Reimbursements by Third Party Payers – A Stumbling Block

Molecular Diagnostics and Intellectual Property

Business Opportunities in the Offing

Medical Training and Practice Challenges  
Hurdles All the Way for Companies Eyeing Molecular Diagnostics  
Integration of Molecular Diagnostics into Therapeutics  
Molecular Diagnostics – Moving from Centralization to Decentralization

## **6. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS – ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS**

Introduction  
Enrichment  
Filtration (iSET)  
Density Gradient  
Immuno-magnetic Cell Enrichment  
Advantages of Different CTC Enrichment Procedures  
AdnaTest  
Identification

### **1. PCR-BASED ANALYSIS**

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  
RT-qPCR

### **2. CYTOMETRIC METHODS**

Fiber-Optic Array Scanning Technology (FAST)  
Laser Scanning Cytometry (LSC)  
Flow Cytometry  
CellSearch  
CTC-Chip  
Enzyme-linked Epithelial Immunospot Assay (ELISPOT)  
Fluorescence In Situ Hybridization (FISH)  
Vita-Assay®  
TelomeScan  
CytoTrack  
Some Other Methods for Detection of CTCs  
Characterization  
Chemo-Sensitivity Testing of CTCs

## **7. CANCER STEM CELLS (CSCS) - BIOLOGY, ISOLATION, CSC SURFACE**

## **MARKERS, AND SIGNALING PATHWAYS**

Introduction

Differences between Normal Stem Cells and Cancer Stem Cells

Milestones in Stem Cell and Cancer Stem Cell Research

Origin

Hierarchical versus Stochastic Models of Tumour Cell Heterogeneity

Isolation of Cancer Stem Cells

Characteristics of Cancer Stem Cells

Resistance to Chemotherapy

Resistance to Radiation

Invasion or Metastatic Activity

CSC Markers

EpCAM (Epithelial Cell Adhesion Molecule)

CD133 (prominin 1)

### **ALDH**

### **CD90 (THY1)**

### **CD44 (PGP1)**

### **CD24 (HSA)**

Surface Markers Used for the Identification of CSCs

Cancer Stem Cell (CSC) Markers by Disease

Metastatic Cancer Stem Cells

## **Table 11. Cancer Stem Cells in Solid Tumors**

Pathways Involved in the Maintenance of CSCs

p53 Pathway

Activation of Receptor Tyrosine Kinase Pathway

Notch Pathway

Retinoblastoma Pathway

Wnt and Sonic Hedgehog Pathways

### **BMI-1**

Research Indicates Diabetes Drug Metformin Effective against Pancreatic Cancer Stem Cells

Research Leads to Development of Novel Chemical Inhibitors that Target Cancer Stem Cells

## **8. PRODUCT LAUNCHES AND INTRODUCTIONS**

EU Authorisation for ANGLE's Parsortix Cancer Diagnostic Device

ANGLE Launches Parsortix Device into the Research Market

Promab Introduces New Range of Cancer Stem Cells Solutions

Clearbridge BioMedics Unveils ClearCell® FX Cancer Cell Enrichment System

Fluxion Introduces New IsoFlux System CTC Technology

Cynvenio Launches LiquidBiopsy Lab Service

Biocept Launches OncoCEE-BR

ApoCell to Launch ApoStream

## **9. RECENT INDUSTRY ACTIVITY**

Stem Cell Therapeutics and University of York Ink Option Agreement

Veridex Undergoes Name Change to Janssen Diagnostics

Janssen Diagnostics and Arno Therapeutics Ink Collaboration Agreement

Veridex Enters into Agreement with LabCorp

Stemline Therapeutics Obtains Orphan Drug Designation for SL-401

ANGLE Announces Test Results of Parsortix Non-Invasive Cancer Diagnostic Product

University Health Network Signs Definitive License Agreement with Stem Cell Therapeutics

Verastem Inks Agreement with LabCorp®

Verastem Receives Orphan Drug Designation for Defactinib from US FDA

Lonza Partners with Eclipse

Verastem Signs Agreement with Pfizer to Acquire Exclusive In-License Rights for VS-6063

ScreenCell Inks Global Distribution Agreement with Affymetrix

Dainippon Sumitomo Pharma to Take Over Boston Biomedical

Bionomics Takes Over Eclipse Therapeutics

BioView Signs Commercial Collaboration Agreement with ScreenCell

Coare Enters into a Services and Co-Marketing Alliance with ChemDiv

Eisai Signs Research Agreement with Verastem

Fluxion Biosciences Inks Collaboration Agreement with Rubicon Genomics

Transgenomic Enters into Partnership with MD Anderson Cancer Center

Transgenomic Collaborates with NYU Langone Medical Center

Veridex Receives China SFDA Approval for CellSearch® CTC Test for Breast Cancer

ScreenCell Signs Global Collaboration and Distribution Agreement with Transgenomic

OncoMed Pharmaceuticals Extends Collaboration with Bayer Healthcare for New Cancer Drug

Veridex Partners with Massachusetts General Hospital for CTC Technology

## **10. FOCUS ON SELECT MAJOR PLAYERS IN CTC DIAGNOSTICS**

Adnagen GmbH (Germany)

ApoCell, Inc (US)

Biocep LTD (Israel)

Biocept, Inc. (US)

Biofluidica Microtechnologies LLC (US)

Celltrafix Inc. (US)

Clearbridge Biomedics (Singapore)

Creatv Microtech, Inc (US)

Cynvenio Biosystems, Inc. (US)

Ikonisys, Inc. (US)

IVDiagnostics, Inc. (US)

Janssen Diagnostics LLC (US)

Epic Biosciences Inc (US)

RARECELLS SAS (Italy)

SCREENCELL (France)

Stemcell Technologies, Inc. (Canada)

## **11. SELECT MARKET PARTICIPANTS IN THE CANCER STEM CELLS (CSCS) SPACE**

Alchemia Limited (Australia)

Amgen Inc. (US)

Exelixis, Inc. (US)

Formula Pharmaceuticals (US)

GlaxoSmithKline Plc. (UK)

Geron Corp. (US)

Infinity Pharmaceuticals (US)

Kalobios Pharmaceuticals Inc. (US)

Novartis AG (Switzerland)



OncoMed Pharmaceuticals, Inc. (US)  
Pfizer, Inc. (US)  
Roche Diagnostics (Switzerland)  
Verastem, Inc. (US)

## 12. GLOBAL MARKET PERSPECTIVE

**Table 12.** World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 13.** World Historic Review for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

**Table 14.** World 15-Year Perspective for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

## III. MARKET

### 1. THE UNITED STATES

#### A. Market Analysis

US Diagnostics Market: An Overview

CTC Diagnostics in the US – Set for a Strong Growth

Cancer Incidence in the US

**Table 15.** New Cancer Cases in the US by Gender and Affected Site: 2012

**Table 16.** New Cancer Cases in Males in US by Leading Site: 2012 (includes corresponding Graph/Chart)

**Table 17.** New Cancer Cases in Females in US by Leading Site: 2012 (includes corresponding Graph/Chart)

Research Breakthroughs in the US CTC Market

Product Launches

Strategic Corporate Development

Select Key Players in CTC Market

Select Key Players in CSC Market

B. Market Analytics

**Table 18.** The US Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 19.** The US Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

## **2. CANADA**

A. Market Analysis

Cancer Incidence in Canada

**Table 20.** New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart)

**Table 21.** New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart)

**Table 22.** New Cancer Cases in Canada by Age Group: 2012 (includes corresponding Graph/Chart)

Strategic Corporate Development

Stemcell Technologies, Inc. – A Key Player

B. Market Analytics

**Table 23.** Canadian Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 24.** Canadian Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

### **3. JAPAN**

A. Market Analysis  
Strategic Corporate Development  
B. Market Analytics

**Table 25.** Japanese Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 26.** Japanese Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

### **4. EUROPE**

A. Market Analysis  
Insight into Molecular Diagnostics Markets in Europe

**Table 27.** European IVD Market for Select Countries (2010) - Market Value in US\$ Million for Spain, UK, Germany, Italy, France, Poland, Netherlands, Belgium, Denmark, Portugal, Austria, Sweden, Bulgaria and Lithuania (includes corresponding Graph/Chart)

Debt Crisis in Europe Affects Healthcare Industry  
Healthcare System.... in a State of Transition?  
Cancer Trends

**Table 28.** Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)

ANGLE's Parsortix Cancer Diagnostic Device Obtains EU Approval

B. Market Analytics

**Table 29.** European Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 30.** European Historic Review for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

**Table 31.** European 15-Year Perspective for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

#### **4A. FRANCE**

A. Market Analysis

Screencell – A Key Player

B. Market Analytics

**Table 32.** French Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 33.** French Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

#### **4B. GERMANY**

- A. Market Analysis
  - An Overview of Molecular Diagnostics
  - Key Player
- B. Market Analytics

**Table 34.** German Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 35.** German Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

#### **4C. ITALY**

- A. Market Analysis
  - Rarecells Sas – A Key Player
- B. Market Analytics

**Table 36.** Italian Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 37.** Italian Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

#### **4D. THE UNITED KINGDOM**

- A. Market Analysis
  - Product Launch
  - Strategic Corporate Developments
  - GlaxoSmithKline Plc. – A Key Company Focusing on CSC Therapeutics
- B. Market Analytics

**Table 38.** The UK Recent Past, Current & Future Analysis for Circulating Tumor Cells

(CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 39.** The UK Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

#### **4E. SPAIN**

Market Analysis

**Table 40.** Spanish Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 41.** Spanish Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

#### **4F. RUSSIA**

Market Analysis

**Table 42.** Russian Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 43.** Russian Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

#### **4G. REST OF EUROPE**

A. Market Analysis

Select Players in CSC Markets

B. Market Analytics

**Table 44.** Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 45.** Rest of Europe Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

## 5. ASIA-PACIFIC

A. Market Analysis  
Cancer Trends in Asia-Pacific

**Table 46.** Cancer Incidence in Asia-Oceania by Site: 2011 (in Thousands) (includes corresponding Graph/Chart)

India

China

CellSearch Obtains Approval for Metastatic Breast Cancer Detection in China  
Product Launch

Strategic Corporate Developments

Key Players

B. Market Analytics

**Table 47.** Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 48.** Asia-Pacific Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

## 6. REST OF WORLD

A. Market Analysis  
Key Player

## B. Market Analytics

**Table 49.** Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)

**Table 50.** Rest of World Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 66 (including Divisions/Subsidiaries - 67)

The United States (46)

Canada (3)

Japan (2)

Europe (9)

    France (3)

    Germany (2)

    The United Kingdom (1)

    Rest of Europe (3)

Asia-Pacific (Excluding Japan) (4)

Middle East (3)



## I would like to order

Product name: Circulating Tumor Cells and Cancer Stem Cells Technologies: Market Research Report

Product link: <https://marketpublishers.com/r/C62E23E7420EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C62E23E7420EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970